Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Concomitant Hybrid Versus Catheter Ablation for Reinforcing Therapeutic Effect of Atrial Fibrillation With Hypertrophic Cardiomyopathy

NCT05610215 is registered in ClinicalTrials.gov with China National Center for Cardiovascular Diseases as lead sponsor.

NCT NCT05610215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05610215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Concomitant Hybrid Versus Catheter Ablation for Reinforcing Therapeutic Effect of Atrial Fibrillation With Hypertrophic Cardiomyopathy
Lead sponsor
China National Center for Cardiovascular Diseases
Phase
Not applicable
Overall status
Recruiting
Start date
February 11, 2023
Completion date
December 31, 2026
Enrollment
66 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, cardiomyopathy, hypertrophic, radiofrequency ablation